COMPAL’ Medical Business Unit, together with its group subsidiaries — Penten Smart Biomedicine Co., Ltd., Qinli Technology Co., Ltd., Hongzhi Biomedicine Co., Ltd. and Raypal Biomedicine Co., Ltd. — will jointly participate in the 11th Asian Conference on Tumor Ablation (ACTA 2025). The exhibition, under the theme of “Precision, Safety, Smart Healthcare,” will comprehensively present the integrated innovation achievements of COMPAL’s medical-ecosystem, and showcase a number of representative smart-medical products, thereby fully demonstrating the Group’s R&D strength and its hardware-software integration capabilities in the smart-healthcare field.
The 11th ACTA conference will be held from 25 to 27 October 2025 at the Grand Hotel Taipei, with the conference theme “Back to the Beginning”. It focuses on the latest developments in interventional tumour therapy, image-guided technologies and artificial intelligence (AI) in clinical applications. The event brings together the world’s top experts in tumour ablation to share clinical cases and exchange techniques, driving precision-medicine practice and international collaboration.
At this joint exhibition, COMPAL and its subsidiaries will highlight five innovative technologies and products, underscoring the Group’s deep cultivation in smart healthcare:
• AblatePal™ RF Ablation System: Taiwan’s first domestically-developed advanced radio-frequency ablation system designed for tumour treatments, combining high performance and safety to achieve precise and stable ablation therapy.
• Hand-held Ultrasound: Penten’s miniaturised ultrasound device features low energy consumption and high image quality, with a compact, portable design uninhibited by time or space constraints — connectable to a mobile device for immediate scanning, breaking down environmental and distance barriers.
• 3-in-1 Glucometer: Integrates glucose, total-cholesterol and uric-acid testing functions to help users monitor metabolic status and provide a one-stop monitoring solution for chronic-disease management.
• AI EEG Analysis System: A non-invasive electroencephalography (EEG) analysis technology capable of real-time, accurate assessment of depression and dementia risk, advancing digital health applications.
• Regenerative-Medicine R&D & Technology: Focused on regenerative medicine and cell therapy, combining immune cells, stem cells and exosome technologies to build a clinical-grade preparation and application platform.
This joint exhibition not only demonstrates the Group’s diversified achievements across medical devices, digital health and regenerative medicine, but also strengthens COMPAL’s medical-ecosystem innovation capabilities through collaboration with its subsidiaries. Looking ahead, COMPAL will continue to deepen its smart-healthcare technology deployment and actively integrate AI, IoT and cloud technologies, striving to provide smart-healthcare solutions with both clinical value and human-centred care.
About COMPAL and Its Medical Subsidiaries
Founded in 1984, COMPAL has grown into a leading manufacturer in the notebook and smart-device industry, with a professional management team and strong R&D capability. Working with partners across various sectors, it continuously innovates and foresees new developments, realises smart technology, and delivers high-quality service through rich industry experience—its breakthrough product designs have repeatedly won international awards. In 2025, the company was ranked among Taiwan’s top-7 manufacturing enterprises by CommonWealth Magazine, and has for years been listed in Forbes Global 2000. In recent years, COMPAL has actively developed emerging businesses including cloud servers, automotive electronics and smart healthcare—leveraging its hardware-software integration advantages in R&D and manufacturing to develop related solutions. For more information, please visit www.COMPAL.com
AblatePal™
Launched officially in 2024, AblatePal is Taiwan’s first domestically-developed advanced radio-frequency ablation system designed for thyroid nodules, liver cancer and soft-tissue treatment. It features an exclusive constant-power algorithm that ensures stable energy output and more precise ablation. It has obtained clinical certifications in Taiwan, the U.S. (FDA), Thailand and Malaysia, demonstrating international-grade quality and safety, offering doctors and patients a more assured treatment experience. For more information, please visit https://iomt.COMPAL.com/MPG
Penten Smart Biomedicine
Founded in 2019, the company’s team encompasses R&D, design, manufacturing, marketing and sales. With a clinical-demand focus, it continuously optimises clinical workflows and meets customised requirements, and has obtained certifications such as ISO 13485, FDA, CE MDR, TFDA. It is dedicated to providing high-quality, safe and effective products and delivering superior after-sales service. For more information, please visit https://acohealthcare.com/
Qinli Biotechnology
Founded in 1999, specialising in in-vitro diagnostics (IVD) and animal-testing products, Qinli has two major brands: BeneCheck™, which focuses on human health testing with products covering glucose, uric-acid, cholesterol, blood ketones, haemoglobin, etc., and in 2025 received EU IVDR certification—becoming Taiwan’s first manufacturer to obtain IVDR for a glucose system; SANCheck™, designed for animal health, offering blood-test solutions for dairy cows, horses and pets to enable precision care. For more information, please visit https://www.glbiotech.com/
Hongzhi Biomedicine
Established in 2019 by COMPAL and the research team of Prof. Yi-Hong Liu of National Yang Ming Chiao Tung University’s Department of Electrical Engineering, the company’s vision is to promote mental-health via EEG and AI technologies. Its flagship product “YouKesi™” (U-Sight) system uses AI models to analyse 90-second EEGs and provide objective indicators of depression risk. For more information, please visit https://www.hipposcreen-nc.com/
Raypal Biomedicine
Founded in 2016, the company is composed of a cross-disciplinary technical team with strong master’s and doctoral backgrounds, combining cell biology, biomedical processing and translational-medicine practice to build clinical-grade regenerative-medicine R&D capability. The company has a dual GTP cell-preparation centre, offering stable, high-viability immune-cell and stem-cell therapies, and provides one-stop regenerative-medicine CDMO services encompassing process development, technology transfer, GTP-grade preparation, release testing and cold-chain logistics. Meanwhile, they extend regenerative medicine into daily wellness and have launched innovative medical-cosmetic products. For more information, please visit https://www.raypal-bio.com/
Media Contact
Jack Wang Vice president and Spokesperson +886-2-8797-8588 Investor@COMPAL.com